Bibliography
- Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;22:866-73
- Lebwohl M. Psoriasis. Lancet 2003;361:1197-204
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59
- Kragballe K, Wildfang IL. Calcipotriene (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 1990;282:164-7
- Oxholm A, Oxholm P, Staberg B, Bendtzen K. Expression of interleukin-6-like molecules and tumour necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC 903). Acta Derm Venereol 1989;69:385-90
- Guyre PM, Girard MT, Morganelli PM, Manganiello PD. Glucocorticoid effects on the production and actions of immune cytokines. J Steroid Biochem 1988;30:89-93
- Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriene and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006;20:39-44
- Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriene and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008;217:321-8
- Rigopoulos D, Gregoriou S, Daniel III CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009;218:338-41
- Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729-36
- Morimoto S, Kumahara Y. A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med J Osaka Univ 1985;35:51-4
- Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem 2001;8:1661-79
- Jensen AM, Llado MB, Skov L, et al. Calcipotriene inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol 1998;139:984-91
- Lee E, Jeon SH, Yi JY, et al. Calcipotriene inhibits autocrine phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem Biophys Res Commun 2001;284:419-25
- Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998;38:1010-1
- Simonsen L, Hoy G, Didriksen E, et al. Development of a new formulation combining calcipotriene and betamethasone diproprionate in an ointment vehicle. Drug Dev Ind Pharm 2004;30:1095-102
- Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol 1997;37:S55-8
- Lebwohl M, Menter A, Koo J, Feldman S. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2003;50:416-30
- van de Kerkhof PC, Franssen M, de La Brassine M, Kuipers M. Calcipotriene cream in the morning and ointment in the evening: a novel regimen to improve compliance. J Dermatol Treatment 2001;12:75-9
- Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriene/betamethasone formulation is a highly effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-93
- Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriene/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate and calcipotriene in psoriasis vulgaris. Acta Derm Venerol 2002;82:131-5
- Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54
- Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriene/betamethasone dipropionate followed by calcipotriene alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004;209:308-13
- Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat 2007;18(6):361-5
- Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriene and betamethasone dipropionate (once or twice daily) compared to calcipotriene (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-23
- Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriene/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-60
- van de Kerkhof PCM, Franssen MEJ. Psoriasis of the scalp: diagnoses and management. Am J Clin Dermatol 2001;2:159-65
- Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008;217:107-13
- van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriene plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009;160:170-6
- Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008;59:455-63
- Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27
- Gudjónsson JE, Kárason A, Antonsdóttir AA, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002;118:362-5
- Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis clinically important, potentially treatable and often overlooked. Rheumatology 2004;43:790-4
- Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 2000;19:301-5
- de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nail associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996;193:300-3
- De Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000;25:357-62
- Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open prospective study. Br J Dermatol 2003;149:1207-9
- Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008;88:279-80
- Saraceno R, Griffiths CEM. A European perspective on the challenges of managing psoriasis. J Am Acad Dermatol 2006;54:S81-4
- Van De Kerkhof PC. The impact of a two compound product containing calcipotriene and betamethasone dipropionate (Daivobet®/Dovobet®) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004;151:663-8
- Ortonne JP, Ganslandt C, Tan J, et al. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. J Eur Acad Dermatol Venereol 2009;23:919-26
- Dytoc MT, Kossintseva I, Ting PT. First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol 2007;157:615-8
- Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002;138:99-105
- Jablonska S, Blaszczyk M. Scleroderma and sclerotic skin conditions: unapproved treatments. Clin Dermatol 2002;20:634-7
- Cunningham BB, Landells ID, Langman C, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998;39:211-5
- Bottomley WW, Jutley J, Wood EJ, et al. The effect of calcipotriol on lesional fibroblasts from patients with active morphoea. Acta Derm Venereol 1995;75:364-6
- Kang S, Yi S, Griffiths CEM, et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998;138:77-83
- Sotiriadis D, Patsatsi A, Sotiriou E, et al. Acrodermatitis continua of Hallopeau on toes successfully treated with a two-compound product containing calcipotriol and betamethasone dipropionate. J Dermatolog Treat 2007;18:315-8
- Njoo MD, Spuls PI, Bos JD. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998;134:1532-40
- Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionte and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006;20:269-73
- Peeters P, Ortonne JP, Sitbon R, Guignard E. Cost-effectiveness of once-daily treatment with calcipotriene/betamethasone dipropionate followed by calcipotriene alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology 2005;211:139-45